A Democratic bill with 5 Republican cosponsors · See all 7 cosponsors
Last activity — Referred to the Committee on Energy and Commerce, and in addition to the Committees on Ways and Means, and the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
In committee
Introduced and handed to a committee in the chamber it started in.
The committee holds it, and most bills are never heard from again. A hearing or a committee vote would be news; silence is the usual outcome, and it kills the bill without anyone voting against it.
Its path through Congress
- Introduced
- In Committee
What this bill would do
The Global Fairness in Drug Pricing Act aims to lower prescription drug costs by aligning U.S. prices with international benchmarks. The Secretary of Health and Human Services is tasked with proposing a plan to impose most-favored-nation price targets to ensure U.S. prices are comparable to those in developed countries. Additionally, the bill directs the Secretary to address circumstances under which individuals can import drugs from countries with lower costs. It also mandates enforcement against anticompetitive practices by pharmaceutical manufacturers. Finally, the bill requires a study on whether manufacturer behaviors impair national security or force patients to subsidize global research.
Yes· 3 of 12
- Scored +9
Does this lower the price of prescription medicines?
The bill specifically aims to reduce prescription drug costs through international price benchmarking and importation waivers.
- Scored +8
Would households on low incomes be better off under this?
Reducing the cost of essential medications provides substantial relief to low-income households.
- Scored +7
Would people over 65 be better off under this?
Lower prescription drug costs significantly benefit the senior population who rely heavily on medications.
The opposite
- Scored -4
Would business owners be better off under this?
Pharmaceutical manufacturers may view these price controls as negative for their business models.
- Scored -2
Does this put more money into scientific research?
The bill investigates if current practices force patients to subsidize global research, which could imply a threat to R&D incentives.
Who it would affect, and how
Potential Positive Impacts for People
-
Price Alignment: The Secretary of Health and Human Services will propose price targets to ensure pharmaceutical prices paid by patients in the United States are comparable to prices in developed countries (Section 2(a)).
-
Drug Importation: The Secretary shall describe circumstances for granting waivers to individuals to import prescription drugs from developed countries with low-cost drugs, provided it poses no risk to public health and safety (Section 2(b)).
-
Direct Purchasing: The Secretary of Health and Human Services shall facilitate direct-to-consumer purchasing programs for manufacturers that sell products at the new determined prices (Section 2(d)).
-
Anticompetitive Protection: The Attorney General and the Chair of the Federal Trade Commission will undertake enforcement actions against anticompetitive practices by pharmaceutical manufacturers (Section 2(c)).
Potential Negative Impacts for People
-
National Security and Subsidy Concerns: A study will be conducted to determine if manufacturer practices impair national security or force patients in the United States to subsidize global pharmaceutical research and development (Section 2(e)).
-
Foreign Market Pricing: The study will also look into whether manufacturer practices involve the suppression of drug prices in foreign markets below fair market value (Section 2(e)).
Groups and Interests Ranking
Every group the model scored this bill for, from -10 to +10. Tap or hover a score for the reason it gave.
- Demographic And Interest Groups
- Would households on low incomes be better off under this? — Reducing the cost of essential medications provides substantial relief to low-income households. Would retired people be better off under this? — Lower drug costs are highly beneficial for retirees on fixed incomes. Would people over 65 be better off under this? — Lower prescription drug costs significantly benefit the senior population who rely heavily on medications. Would middle-income households be better off under this? — Lower drug costs provide relief to middle-class household budgets. Would people with disabilities be better off under this? — Reduced costs for medications can assist those living with disabilities. Would veterans be better off under this, taking everything together? — Lower drug costs assist veterans who may rely on prescription medications. Would business owners be better off under this? — Pharmaceutical manufacturers may view these price controls as negative for their business models.
- Healthcare
- Does this lower the price of prescription medicines? — The bill specifically aims to reduce prescription drug costs through international price benchmarking and importation waivers. Does this make health care easier to get in general? — Increased affordability through lower drug prices can improve overall healthcare access for patients.
- Governance And Ideology
- Does this give the federal government more power? — The bill expands federal authority over drug pricing through rulemaking and increased enforcement actions. Does this make what the government does easier for the public to see? — The bill mandates studies and reports to Congress regarding pharmaceutical manufacturer behaviors.
- Economy And Finance
- Does this give people more protection from unfair business practices? — The bill enhances consumer protection by targeting anticompetitive pharmaceutical pricing and facilitating direct-to-consumer purchases.
- Social Issues And Justice
- Is this likely to lift people out of poverty? — Lower drug costs provide direct financial relief to low-income households.
- Education And Technology
- Does this put more money into scientific research? — The bill investigates if current practices force patients to subsidize global research, which could imply a threat to R&D incentives.
- 2/24/2026
- 1 Cosponsor added.
- 11/7/2025
- 1 Cosponsor added.
- 10/17/2025
- 1 Cosponsor added.
- 6/3/2025
- 1 Cosponsor added.
- 5/19/2025
- Referred to the Committee on Energy and Commerce, and in addition to the Committees on Ways and Means, and the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
- 3 Cosponsors added.
- Introduced in House
Andy BiggsRepublican · Arizona
Tom BarrettRepublican · Michigan
Elijah CraneRepublican · Arizona
Marjorie GreeneRepublican · Georgia
Marcy KapturDemocrat · Ohio
Anna Paulina LunaRepublican · Florida
Suhas SubramanyamDemocrat · Virginia